Nonapeptide-1 turns up in brightening serums and melasma formulas, and it has one of the smallest published files of any peptide this site has covered. Four records. Reading all four takes about twenty minutes, and doing so changes what the ingredient's evidence appears to say.
The molecule
PubChem CID 10418849: formula C61H87N15O9S, 1,206.5 g/mol, nine amino acid residues, one of them sulphur-bearing.
That weight matters here more than usual. The 500-dalton heuristic puts the practical ceiling for passive penetration of intact stratum corneum at roughly 500 Da. Nonapeptide-1 is about 2.4 times that — heavier than acetyl hexapeptide-8 (887 Da), heavier than Matrixyl's palmitoyl pentapeptide-4 (802 Da), and three times copper tripeptide-1 (402.9 Da), the one common cosmetic peptide that clears the line. Pigment cells sit at the base of the epidermis, so this is a large molecule being asked to travel a long way.
Four records, and only two are about this
Searched 2026-09-20, nonapeptide-1 in the title or abstract returns four papers:
| Year | Journal | What it is |
|---|---|---|
| 2025 | J Am Soc Mass Spectrom | dielectric material optimisation for an ionisation source — an instrumentation paper |
| 2024 | Int J Pharm | EGCG loaded in nonapeptide-1-conjugated mesoporous silica nanoparticles |
| 2022 | Postepy Dermatol Alergol | tea polyphenols and UVA-induced melanogenesis via the α-MSH–MC1R pathway |
| 2021 | Indian J Dermatol Venereol Leprol | randomized controlled pilot, proprietary combination vs sunscreen in melasma |
The 2025 paper uses the peptide as an analyte in a mass-spectrometry method development exercise; it is not a skin study. The 2022 paper investigates the pathway nonapeptide-1 is claimed to act on, but tests tea polyphenols, not the peptide.
That leaves two.
In the 2024 study, the peptide is the envelope
Huang and colleagues, International Journal of Pharmaceutics 2024, is the paper a search for this ingredient most often surfaces, and its title contains both the word nonapeptide-1 and the words skin photoaging. It is easy to read as evidence for the ingredient. It is not.
The study builds mesoporous silica nanoparticles, conjugates nonapeptide-1 to their surface, and loads them with epigallocatechin-3-gallate — green tea's catechin, and a compound with its own large literature. The nanoparticles regulate EGCG release and add UV photostability. The reported results — a melanin inhibition rate 5.22 times, and a tyrosinase inhibition rate 1.57 times, that of free EGCG — are comparisons of loaded nanoparticles against free EGCG.
Nonapeptide-1's role in that design is targeting: it is the address on the parcel, chosen because of its described melanin-transfer interference. The active whose effect is measured is EGCG. A page citing this study as evidence that nonapeptide-1 brightens skin has read the title and not the design — the same failure mode as citing a trial for a comparison it has no arm for.
The one randomized trial missed significance, and could not have attributed it anyway
Chatterjee, Neema and Rajput, Indian Journal of Dermatology, Venereology and Leprology 2021: a prospective, double-blinded, parallel-group randomized controlled pilot study, 46 subjects, 23 per arm, over eight months in three phases. Both groups first used a triple combination for eight weeks. Then the case group applied a proprietary product and the control group applied sunscreen; sunscreen was used by everyone throughout.
Two things about it, both from the abstract:
First, the result. The case group showed improvement in melasma severity score and in mean melanin index measured by mexameter, but it "did not attain statistical significance as compared to the control group". The melasma area and severity index did fall consistently in the case group while rising in the control group, and the authors conclude the combination is more effective as maintenance. The limitations they name themselves are small sample size and short follow-up.
Second, and decisive for an ingredient page: the proprietary combination contained phenyl ethyl resorcinol, nonapeptide-1, aminoethyl phosphinic acid, antioxidants and sunscreen. Phenyl ethyl resorcinol is a well-documented tyrosinase inhibitor in its own right. Five components, one arm. No result from this trial can be assigned to the peptide, and the trial does not try to.
What the mechanism literature holds
The claim for nonapeptide-1 is interference with α-MSH signalling, the pathway that drives melanocytes to produce and hand off pigment. That pathway is genuinely well studied: on 2026-09-20 PubMed held 17 records joining an α-MSH antagonist to melanogenesis. None of them tests this INCI ingredient on human skin. The pathway's credibility and the ingredient's evidence are separate things, and the first is routinely offered in place of the second.
What this supports saying
- Nonapeptide-1 is a nine-residue peptide of 1,206.5 g/mol, well above the weight at which passive skin penetration is usually considered plausible.
- It has four indexed papers; two are about skin.
- In the more prominent of those two it is the nanoparticle's targeting ligand, not the tested active.
- The single randomized trial containing it did not reach significance on melasma severity or melanin index, and combined the peptide with four other components including a sunscreen.
- The pathway it targets is well characterised. The ingredient's own effect on human skin has not been measured in the indexed literature.
Where to go next
- What peptides do for skin — the four mechanism classes, and where each has actually been measured.
- Peptides for skin: the whole category, counted — the census and the molecular-weight table this entry sits in.
- sh-Oligopeptide-1 — the other ingredient on this site whose INCI name misdescribes its size.
- How to read a peptide ingredient list — position, the one-percent line, and what a label can tell you.
Sources
- PubChem CID 10418849 — nonapeptide-1, read 2026-09-20.
- Huang ZJ, Zhou XH, Wen WQ, et al. Enhanced skin benefits of EGCG loaded in nonapeptide-1-conjugated mesoporous silica nanoparticles to reverse skin photoaging. Int J Pharm 2024;665:124690.
- Chatterjee M, Neema S, Rajput GR. A randomized controlled pilot study of a proprietary combination versus sunscreen in melasma maintenance. Indian J Dermatol Venereol Leprol 2021;88(1):51-8.
- Bos JD, Meinardi MMHM. The 500 Dalton rule. Exp Dermatol 2000.
- PubMed counts run 2026-09-20, validated against a control term.